Back to Search
Start Over
Evidence of hypoglycemic, lipid-lowering and hepatoprotective effects of the Bixin and Bixin: β-CD inclusion compound in high-fat-fed obese mice.
- Source :
-
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2018 Oct; Vol. 106, pp. 363-372. Date of Electronic Publication: 2018 Jul 11. - Publication Year :
- 2018
-
Abstract
- Associations between obesity, diabetes type II, and steatosis have long been recognized. However, a pharmacotherapy that acts in a multifactorial manner controlling the interactions between these conditions is not available. A variety of natural plants, functional fatty acids, and other natural dietary compounds have been used in various anti-obesity products. We investigated the effects of oral administration of an antioxidant carotenoid pigment Bixin and Bixin: β-Cyclodextrin in an obese murine model. C57BL/6 male mice (4-5 weeks) received standard diet (2.18 kcal per 1 g) (CT) and high-fat diet (4.38 kcal per 1 g) (CT/OB, BIX and BIX/βCD) (n = 10 per group). After 16 weeks, the BIX and BIX/βCD were treated by gavage (100 μL day-1) for six weeks, with water (CT and CT/OB groups) and (50 mg kg-1 day-1), Bixin (BIX group) or Bix: β-CD (BIX/βCD). Body weight, Lee's Index, adiposity, CHT, TG, CHT/HDL-c, glucose levels (metabolic markers) and, liver markers (AST and ALT) were determined. All metabolic and liver parameters exhibited down-regulation after oral administration of BIX and BIX/βCD. Particularly relevant was Lee's Index and adiposity in BIX- and BIX/βCD-treated groups (339.18 g/cm -BIX and 327.58 g/cm -BIX/βCD vs. 360.68 g/cm -CT/OB animals), this finds associated with the insulin sensitivity test, showed a clear association between reduction of adipose tissue and decrease of peripherical insulin resistant. In conclusion, our study suggested that the oral administration of the Bixin and Bix: β-CD inclusion compound improved the metabolic parameters evaluate in obese mice, being more palatable and hepatoprotective.<br /> (Copyright © 2018. Published by Elsevier Masson SAS.)
- Subjects :
- 3T3-L1 Cells
Adipocytes drug effects
Adipocytes metabolism
Adipocytes pathology
Adiposity drug effects
Animals
Biomarkers blood
Blood Glucose metabolism
Disease Models, Animal
Dose-Response Relationship, Drug
Fatty Liver blood
Fatty Liver etiology
Fatty Liver pathology
Glucose Metabolism Disorders blood
Glucose Metabolism Disorders etiology
Liver metabolism
Liver pathology
Male
Mice
Mice, Inbred C57BL
Obesity blood
Obesity etiology
Obesity pathology
Time Factors
Blood Glucose drug effects
Carotenoids pharmacology
Diet, High-Fat
Fatty Liver prevention & control
Glucose Metabolism Disorders prevention & control
Hypoglycemic Agents pharmacology
Hypolipidemic Agents pharmacology
Lipids blood
Liver drug effects
Obesity drug therapy
beta-Cyclodextrins pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1950-6007
- Volume :
- 106
- Database :
- MEDLINE
- Journal :
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- Publication Type :
- Academic Journal
- Accession number :
- 29966982
- Full Text :
- https://doi.org/10.1016/j.biopha.2018.06.144